# Blue Ocean Capital Group

> Blue Ocean Capital Group is a VC fund in Shenzhen backing Biotechnology and Medical. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Shenzhen, China
- Total investments: 7
- Last investment: Jul 2026
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.bocggp.com/

Blue Ocean Capital Group (“BOCG”) is an emerging equity investment house, specializing in healthcare investment, with $300 million equivalent in assets under management（AUM）accumulatively. BOCG has been committed to in-depth investment and value creation. Through effective investment management, BOCG brings positive change to investees and createslong-term value for investors.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 71% |
| Medical | 3 | 43% |
| Health Care | 3 | 43% |
| Genetics | 2 | 29% |
| Therapeutics | 2 | 29% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 43% |
| Series C | 2 | 29% |
| Angel | 1 | 14% |
| Series B | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Torrey Pines Medicine | Torrey Pines Medicine is a biotechnology business focused on creating next-generation ultra-long-acting peptide therapies for metabolic illnesses. |  | Angel | Jul 28, 2026 |  |
| Signet Therapeutics | Signet Therapeutics is a cutting-edge firm that conducts research and development on cancer-targeted drugs using AI and organoid disease models. | $11.5M | Series A | Jan 14, 2026 |  |
| CureGenetics | Cure Genetics is a biotechnology company developing cutting-edge applications of technologies in innovative medicines and molecular diagnostics for the next-generation treatment of cancers and genetic diseases. | $60M | Series B | Jan 05, 2022 |  |
| Boan Biotech | Boan Biotech is a biopharmaceutical company developing therapeutic antibodies with a focus on key therapeutic areas including oncology, metabolism, autoimmunity, and ophthalmology. | $105.6M | Series A | Jan 05, 2021 |  |
| Huayin Health | Huayin Health is a comprehensive healthcare and medical service group, focuses on providing laboratory and pathological services. | $85M | Series C | Apr 08, 2020 |  |
| Suzhou Ribo Life Science | Suzhou Ribo Life Science is a developer of RNA interference ( RNAi ) technology designed to treat liver diseases. The company's RNA interference ( RNAi ) technology is used to develop nucleic acid therapeutic drugs and related products, enabling healthcare providers to deliver more effective pharmaceuticals to patients. | $28.8M | Series C | Dec 05, 2019 |  |
| Wenge Group | Zhongke Wenge is positioned in the wisdom media big data application, aiming to provide technology engine for China's media transformation and upgrading, and to serve media communication capacity building. The company is facing the influence of China's media, government and enterprises, and is committed to the research and development ofnew media big data technology and systems. It has formed the "Wenhai" new media big data platform, "Wen Ge" central kitchen, "Wen Si" decision-making service. The platform's three major product systems, as well as the “Wenhai” new media data service platform, the “cloud trace” communication monitoring and evaluation system, the “Yunyong” media visualization analysis system, the “Yayi” text semantic analysis component, and the four flagship products. |  | Series A | May 17, 2018 |  |

7 of 7 investments shown.

## Co-investors
- [Advantech Capital](https://shizune.co/investors/profile/advantech-capital) — VC Fund, 2 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together
- [BVCF](https://shizune.co/investors/profile/bioveda-china-fund) — VC Fund, 1 deal together
- [Brill Capital](https://shizune.co/investors/profile/brill-capital) — VC Fund, 1 deal together
- [CAS Star](https://shizune.co/investors/profile/cas-star) — VC Fund, 1 deal together
- [Daxie Yungong Investment](https://shizune.co/investors/profile/daxie-yungong-investment) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Blue Ocean Capital Group invest in?

Blue Ocean Capital Group invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series C stage. Most of the 7 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Blue Ocean Capital Group last invest?

The most recent investment recorded for Blue Ocean Capital Group closed in Jul 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co